| Year |
Citation |
Score |
| 2024 |
Weld ED, Ogasawara K, Fuchs EJ, Louissaint N, Caffo B, Hendrix CW. Mapping Colorectal Distribution of Cell-free and Cell-associated HIV Surrogates Following Simulated Anal Intercourse to Aid Rectal Microbicide Development. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 38346420 DOI: 10.1097/QAI.0000000000003401 |
0.773 |
|
| 2023 |
Marzinke MA, Fogel JM, Wang Z, Piwowar-Manning E, Kofron R, Moser A, Bhandari P, Gollings R, Bushman LR, Weng L, Halvas EK, Mellors J, Anderson PL, Persaud D, Hendrix CW, et al. Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. Antimicrobial Agents and Chemotherapy. e0005323. PMID 36995219 DOI: 10.1128/aac.00053-23 |
0.311 |
|
| 2022 |
Garcia-Cremades M, Hendrix CW, Jayachandran P, Strydom N, Jarlsberg L, Grant R, Celum CL, Martin M, Baeten JM, Marrazzo J, Anderson P, Choopanya K, Vanichseni S, Glidden DV, Savic RM. Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis. Pharmaceutics. 14. PMID 36145549 DOI: 10.3390/pharmaceutics14091801 |
0.302 |
|
| 2022 |
Garcia-Cremades M, Vučićević K, Hendrix CW, Jayachandran P, Jarlsberg L, Grant R, Celum CL, Martin M, Baeten JM, Marrazzo J, Anderson P, Choopanya K, Vanichseni S, Glidden DV, Savic RM. Characterizing HIV-preventive, plasma tenofovir concentrations. A pooled participant-level data analysis from HIV pre-exposure prophylaxis (PrEP) clinical trials. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 35474481 DOI: 10.1093/cid/ciac313 |
0.31 |
|
| 2021 |
McGowan IM, Kunjara Na Ayudhya RP, Brand RM, Marzinke MA, Hendrix CW, Johnson S, Piper J, Holtz TH, Curlin ME, Chitwarakorn A, Raengsakulrach B, Doncel G, Schwartz Icloud Com J, Rooney JF, Cranston RD. An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine / Tenofovir Disoproxil Fumarate. Aids Research and Human Retroviruses. PMID 34541872 DOI: 10.1089/AID.2021.0115 |
0.326 |
|
| 2020 |
Al-Khouja A, Shieh EC, Fuchs EJ, Marzinke MA, Bakshi RP, Hummert P, Ham A, Buckheit KW, Breakey JC, Weld ED, Chen H, Caffo BS, Buckheit RW, Hendrix CW. Examining the Safety, Pharmacokinetics, and Pharmacodynamics of a Rectally Administered IQP-0528 Gel for HIV Pre-Exposure Prophylaxis: a First-in-Human Study. Aids Research and Human Retroviruses. PMID 33371779 DOI: 10.1089/AID.2020.0188 |
0.328 |
|
| 2020 |
Stalter RM, Baeten JM, Donnell D, Spinelli MA, Glidden DV, Rodrigues WC, Wang G, Vincent M, Mugo N, Mujugira A, Marzinke M, Hendrix C, Gandhi M. Urine Tenofovir Levels Measured by a Novel Immunoassay Predict HIV Protection. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32569370 DOI: 10.1093/Cid/Ciaa785 |
0.38 |
|
| 2020 |
Okafor CN, Hucks-Ortiz C, Hightow-Weidman LB, Magnus M, Emel L, Beauchamp G, Kuo I, Hendrix C, Mayer KH, Shoptaw S. Associations between Self-Reported Substance Use Behaviors and PrEP Acceptance and Adherence among Black MSM in the HPTN 073 Study. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 32452970 DOI: 10.1097/Qai.0000000000002407 |
0.357 |
|
| 2019 |
Matthews LT, Jaggernath M, Kriel Y, Smith PM, O'Neil K, Haberer JE, Hendrix C, Baeten JM, Ware NC, Wirth K, Psaros C, Bangsberg DR, Smit JA. Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa. Bmj Open. 9: e027227. PMID 31350241 DOI: 10.1136/Bmjopen-2018-027227 |
0.341 |
|
| 2019 |
Mallayasamy S, Chaturvedula A, Fossler MJ, Sale M, Goti V, Bumpus NN, Marzinke MA, Hendrix CW, Haberer JE. Tenofovir plasma concentration from pre-exposure prophylaxis (PrEP) at the time of potential HIV exposure: a population pharmacokinetic modeling and simulation study involving serodiscordant couples in East Africa. Antimicrobial Agents and Chemotherapy. PMID 31182536 DOI: 10.1128/Aac.00446-19 |
0.398 |
|
| 2018 |
McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, Hendrix CW, Richardson P, Eshleman SH, Andrade A, Chege W, Anderson PL, McCauley M, Farley J, Mayer KH, et al. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing PrEP Regimens in Men who have Sex with Men. Aids (London, England). PMID 30570571 DOI: 10.1097/QAD.0000000000002038 |
0.31 |
|
| 2018 |
McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, Hendrix CW, Richardson P, Eshleman SH, Andrade A, Chege W, Anderson PL, McCauley M, Farley J, Mayer KH, et al. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing PrEP Regimens in Men who have Sex with Men. Aids (London, England). PMID 30557160 DOI: 10.1097/Qad.0000000000002038 |
0.31 |
|
| 2018 |
Pines HA, Strathdee SA, Hendrix CW, Bristow CC, Harvey-Vera A, Magis-Rodríguez C, Martinez G, Semple SJ, Patterson TL. Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border region. International Journal of Std & Aids. 956462418793038. PMID 30170533 DOI: 10.1177/0956462418793038 |
0.349 |
|
| 2018 |
Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Gunawardana M, Dawson LN, Olive TJ, Pyles RB, Baum MM. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc. Plos One. 13: e0201952. PMID 30133534 DOI: 10.1371/Journal.Pone.0201952 |
0.33 |
|
| 2018 |
Hoang T, Date AA, Ortiz Ortiz J, Young TW, Bensouda S, Xiao P, Marzinke M, Rohan L, Fuchs EJ, Hendrix C, Gumber S, Villinger F, Cone RA, Hanes J, Ensign LM. Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. PMID 29802984 DOI: 10.1016/J.Ejpb.2018.05.030 |
0.39 |
|
| 2017 |
Xiao P, Gumber S, Marzinke MA, Date AA, Hoang T, Hanes J, Ensign LM, Wang L, Rohan L, Fuchs EJ, Hendrix C, Villinger F. Hypo-osmolar formulation of TFV enema promotes uptake and metabolism of TFV in tissues and leading to prevention of SHIV/SIV infection. Antimicrobial Agents and Chemotherapy. PMID 29084755 DOI: 10.1128/Aac.01644-17 |
0.383 |
|
| 2017 |
Smith JM, Moss JA, Srinivasan P, Butkyavichene I, Gunawardana M, Fanter R, Miller CS, Sanchez D, Yang F, Ellis S, Zhang J, Marzinke MA, Hendrix CW, Kapoor A, Baum MM. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. Plos One. 12: e0185946. PMID 28982161 DOI: 10.1371/journal.pone.0185946 |
0.311 |
|
| 2017 |
Montgomery ET, Noguchi LM, Dai JY, Pan J, Biggio J, Hendrix C, Isaacs K, Watts DH, Schwartz JL, Piper J, Beigi R. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. Aids and Behavior. PMID 28550377 DOI: 10.1007/S10461-017-1811-9 |
0.321 |
|
| 2016 |
Mayer KH, Safren SA, Elsesser SA, Psaros C, Tinsley JP, Marzinke M, Clarke W, Hendrix C, Wade Taylor S, Haberer J, Mimiaga MJ. Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP". Aids and Behavior. PMID 27848089 DOI: 10.1007/S10461-016-1606-4 |
0.317 |
|
| 2016 |
Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, Asiimwe S, Haberer JE, Morton J, Ngure K, Bulya N, Odoyo J, Tindimwebwa E, Hendrix C, Marzinke MA, et al. Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda. Plos Medicine. 13: e1002099. PMID 27552090 DOI: 10.1371/Journal.Pmed.1002099 |
0.389 |
|
| 2015 |
Dai JY, Hendrix CW, Richardson BA, Kelly C, Marzinke M, Chirenje ZM, Marrazzo JM, Brown ER. Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study. The Journal of Infectious Diseases. PMID 26123563 DOI: 10.1093/Infdis/Jiv333 |
0.322 |
|
| 2015 |
Gunawardana M, Remedios-Chan M, Miller CS, Fanter R, Yang F, Marzinke MA, Hendrix CW, Beliveau M, Moss JA, Smith TJ, Baum MM. Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis. Antimicrobial Agents and Chemotherapy. 59: 3913-9. PMID 25896688 DOI: 10.1128/AAC.00656-15 |
0.302 |
|
| 2014 |
Yang KH, Hendrix C, Bumpus N, Elliott J, Tanner K, Mauck C, Cranston R, McGowan I, Richardson-Harman N, Anton PA, Kashuba AD. A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate. Plos One. 9: e106196. PMID 25350119 DOI: 10.1371/Journal.Pone.0106196 |
0.343 |
|
| 2014 |
Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, ... ... Hendrix C, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. The Lancet. Infectious Diseases. 14: 1055-64. PMID 25300863 DOI: 10.1016/S1473-3099(14)70937-5 |
0.366 |
|
| 2014 |
Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, Mujugira A, Mugo N, Ndase P, Hendrix C, Celum C. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. Journal of Acquired Immune Deficiency Syndromes (1999). 66: 340-8. PMID 24784763 DOI: 10.1097/Qai.0000000000000172 |
0.332 |
|
| 2014 |
Herold BC, Dezzutti CS, Richardson BA, Marrazzo J, Mesquita PMM, Carpenter C, Huber A, Louissaint N, Marzinke MA, Hillier SL, Hendrix CW. Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1 Journal of Acquired Immune Deficiency Syndromes. 66: 65-73. PMID 24457633 DOI: 10.1097/Qai.0000000000000110 |
0.764 |
|
| 2013 |
Avery LB, Zarr MA, Bakshi RP, Siliciano RF, Hendrix CW. Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect. Aids Research and Human Retroviruses. 29: 1434-42. PMID 23601085 DOI: 10.1089/Aid.2013.0031 |
0.75 |
|
| 2013 |
Louissaint NA, Cao YJ, Skipper PL, Liberman RG, Tannenbaum SR, Nimmagadda S, Anderson JR, Everts S, Bakshi R, Fuchs EJ, Hendrix CW. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. Aids Research and Human Retroviruses. 29: 1443-50. PMID 23600365 DOI: 10.1089/Aid.2013.0044 |
0.766 |
|
| 2013 |
Avery LB, Sacktor N, McArthur JC, Hendrix CW. Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration. Antimicrobial Agents and Chemotherapy. 57: 1409-14. PMID 23295919 DOI: 10.1128/Aac.02329-12 |
0.749 |
|
| 2013 |
Avery LB, VanAusdall JL, Hendrix CW, Bumpus NN. Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 422-9. PMID 23166317 DOI: 10.1124/Dmd.112.049601 |
0.743 |
|
| 2013 |
Avery LB, Sacktor N, McArthur JC, Hendrix C. Erratum: Protein-free efavirenz concentrations in cerebrospinal fluid andblood plasma are equivalent: Applying the law of mass action topredict protein-free drug concentration (Antimicrobial Agents and Chemotherapy (2013) 57:3 (1409-1414)) Antimicrobial Agents and Chemotherapy. 57. DOI: 10.1128/Aac.01250-13 |
0.727 |
|
| 2012 |
Chen J, Flexner C, Liberman RG, Skipper PL, Louissaint NA, Tannenbaum SR, Hendrix CW, Fuchs EJ. Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. Journal of Acquired Immune Deficiency Syndromes (1999). 61: 593-9. PMID 23187888 DOI: 10.1097/Qai.0B013E3182717C98 |
0.761 |
|
| 2012 |
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, ... ... Hendrix C, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England Journal of Medicine. 367: 399-410. PMID 22784037 DOI: 10.1056/Nejmoa1108524 |
0.402 |
|
| 2012 |
Louissaint NA, Fuchs EJ, Bakshi RP, Nimmagadda S, Du Y, Macura KJ, King KE, Wahl R, Goldsmith AJ, Caffo B, Cao YJ, Anderson J, Hendrix CW. Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse. The Journal of Infectious Diseases. 205: 725-32. PMID 22279121 DOI: 10.1093/Infdis/Jir841 |
0.777 |
|
| 2012 |
Louissaint NA, Nimmagadda S, Fuchs EJ, Bakshi RP, Cao YJ, Lee LA, Goldsmith J, Caffo BS, Du Y, King KE, Menendez FA, Torbenson MS, Hendrix CW. Distribution of cell-free and cell-associated HIV surrogates in the colon after simulated receptive anal intercourse in men who have sex with men. Journal of Acquired Immune Deficiency Syndromes (1999). 59: 10-7. PMID 21937920 DOI: 10.1097/Qai.0B013E3182373B5E |
0.782 |
|
| 2011 |
Dezzutti CS, Hendrix CW, Marrazzo JM, Pan Z, Wang L, Louissaint N, Kalyoussef S, Torres NM, Hladik F, Parikh U, Mellors J, Hillier SL, Herold BC. Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. Plos One. 6: e23136. PMID 21858008 DOI: 10.1371/Journal.Pone.0023136 |
0.763 |
|
| 2011 |
Avery LB, Bakshi RP, Cao YJ, Hendrix CW. The male genital tract is not a pharmacological sanctuary from efavirenz. Clinical Pharmacology and Therapeutics. 90: 151-6. PMID 21633344 DOI: 10.1038/Clpt.2011.99 |
0.733 |
|
| 2011 |
Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, Shust G, Mesquita PM, Louissaint N, Chen J, Cohen HW, Diament EC, Lee AC, Soto-Torres L, Hendrix CW, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. Plos One. 6: e16475. PMID 21283552 DOI: 10.1371/Journal.Pone.0016475 |
0.77 |
|
| 2011 |
Lu Y, Hendrix C, Celum C, Baeten J, Cowan F, Delany-Moretlwe S, Reid S, Hughes J, Wald A, Corey L. LBO-1.1 Acyclovir achieves lower concentration in African HIV-, HSV-2+ women compared to non-African populations, possibly explaining lower herpes suppression Sexually Transmitted Infections. 87: A350-A350. DOI: 10.1136/Sextrans-2011-050119.1 |
0.368 |
|
| 2009 |
Magill SS, Swoboda SM, Shields CE, Colantuoni EA, Fothergill AW, Merz WG, Lipsett PA, Hendrix CW. The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial. Annals of Surgery. 249: 657-65. PMID 19300221 DOI: 10.1097/SLA.0b013e31819ed914 |
0.613 |
|
| 2008 |
Cao YJ, Ndovi TT, Parsons TL, Guidos AM, Caffo B, Hendrix CW. Effect of semen sampling frequency on seminal antiretroviral drug concentration. Clinical Pharmacology and Therapeutics. 83: 848-56. PMID 17914441 DOI: 10.1038/Sj.Clpt.6100356 |
0.317 |
|
| 2008 |
Hendrix CW, Fuchs EJ, Macura KJ, Lee LA, Parsons TL, Bakshi RP, Khan WA, Guidos A, Leal JP, Wahl R. Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clinical Pharmacology and Therapeutics. 83: 97-105. PMID 17507921 DOI: 10.1038/Sj.Clpt.6100236 |
0.331 |
|
| 2006 |
Magill SS, Swoboda SM, Johnson EA, Merz WG, Pelz RK, Lipsett PA, Hendrix CW. The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients. Diagnostic Microbiology and Infectious Disease. 55: 293-301. PMID 16698215 DOI: 10.1016/j.diagmicrobio.2006.11.011 |
0.766 |
|
| 2006 |
Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Mâsse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. Aids (London, England). 20: 543-51. PMID 16470118 DOI: 10.1097/01.Aids.0000210608.70762.C3 |
0.38 |
|
| 2005 |
FUCHS E, WAHL R, MACURA K, LEAL J, GROHSKOPF L, HENDRIX C. Imaging the distribution and clearance of a rectal microbicide gel and semen surrogate in the lower gastrointestinal tract Clinical Pharmacology & Therapeutics. 77: P60-P60. DOI: 10.1016/J.Clpt.2004.12.120 |
0.352 |
|
| 2004 |
Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, Jackson JB, Coombs RW, Glesby MJ, Flexner CW, Bridger GJ, Badel K, MacFarland RT, Henson GW, Calandra G, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes (1999). 37: 1253-62. PMID 15385732 DOI: 10.1097/01.Qai.0000137371.80695.Ef |
0.319 |
|
| 2004 |
Magill SS, Puthanakit T, Swoboda SM, Carson KA, Salvatori R, Lipsett PA, Hendrix CW. Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients. Antimicrobial Agents and Chemotherapy. 48: 2471-6. PMID 15215096 DOI: 10.1128/AAC.48.7.2471-2476.2004 |
0.633 |
|
| 2004 |
Eddins J, Dimick J, Swoboda S, Talamini M, Pelz R, Hendrix C, Lipsett P. Risk of colonization of central venous catheters: Catheters for total parenteral nutrition vs. other catheters. The Journal of the Association For Vascular Access. 9: 48-49. DOI: 10.2309/1552-8855-9.1.48 |
0.714 |
|
| 2003 |
Dimick JB, Swoboda S, Talamini MA, Pelz RK, Hendrix CW, Lipsett PA. Risk of colonization of central venous catheters: catheters for total parenteral nutrition vs other catheters. American Journal of Critical Care : An Official Publication, American Association of Critical-Care Nurses. 12: 328-35. PMID 12882063 |
0.726 |
|
| 2003 |
Rajagopalan P, Pelz RK, Lipsett PA, Swoboda SM, Rinaldi MG, Hendrix CW. Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit. Pharmacotherapy. 23: 592-602. PMID 12741433 DOI: 10.1592/Phco.23.5.592.32202 |
0.726 |
|
| 2003 |
Jackson JB, Barnett S, Piwowar-Manning E, Apuzzo L, Raines C, Hendrix C, Hamzeh F, Gallant J. A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk. Aids (London, England). 17: 547-53. PMID 12598775 DOI: 10.1097/00002030-200303070-00010 |
0.393 |
|
| 2002 |
Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, Perl TM, Hammond JM, Hendrix CW. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Medicine. 28: 692-7. PMID 12107672 DOI: 10.1007/S00134-002-1276-8 |
0.735 |
|
| 2002 |
Pelz RK, Lipsett PA, Swoboda SM, Merz W, Rinaldi MG, Hendrix CW. Enteral fluconazole is well absorbed in critically ill surgical patients. Surgery. 131: 534-40. PMID 12019407 DOI: 10.1067/msy.2002.123803 |
0.739 |
|
| 2001 |
Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, Lipsett PA. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery. 233: 542-8. PMID 11303137 DOI: 10.1097/00000658-200104000-00010 |
0.751 |
|
| 2001 |
Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Archives of Surgery (Chicago, Ill. : 1960). 136: 229-34. PMID 11177147 DOI: 10.1001/Archsurg.136.2.229 |
0.729 |
|
| 2001 |
Hendrix CW, Hammond JM, Swoboda SM, Merz WG, Harrington SM, Perl TM, Dick JD, Borschel DM, Halczenko PW, Pelz RK, Rocco LE, Conway JE, Brower RG, Lipsett PA. Surveillance strategies and impact of vancomycin-resistant enterococcal colonization and infection in critically ill patients. Annals of Surgery. 233: 259-65. PMID 11176133 DOI: 10.1097/00000658-200102000-00016 |
0.747 |
|
| 2000 |
Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Hammond JM, Hendrix CW. The diagnostic value of fungal surveillance cultures in critically ill patients. Surgical Infections. 1: 273-81. PMID 12594883 DOI: 10.1089/109629600750067200 |
0.741 |
|
| 2000 |
Hendrix CW, Flexner C, Macfarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, Henson GW. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR- 4 chemokine receptor, in human volunteers Antimicrobial Agents and Chemotherapy. 44: 1667-1673. PMID 10817726 DOI: 10.1128/Aac.44.6.1667-1673.2000 |
0.359 |
|
| 2000 |
Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, Perl TM, Hammond JM, Hendrix CW. CandidaInfections: Outcome and Attributable ICU Costs in Critically Ill Patients Journal of Intensive Care Medicine. 15: 255-261. DOI: 10.1046/J.1525-1489.2000.00255.X |
0.737 |
|
| 2000 |
Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, Perl TM, Hammond JM, Hendrix CW. Candida infections: Outcome and attributable ICU costs in critically ill patients Journal of Intensive Care Medicine. 15: 255-261. DOI: 10.1046/j.1525-1489.2000.00255.x |
0.737 |
|
| 1999 |
Petty BG, Black JR, Hendrix CW, Lewis LD, Basiakos Y, Feinberg J, Pattison DG, Hafner R. Escalating multiple-dose safety and tolerance study of oral WR 6026 in HIV-infected subjects: AIDS clinical trials group 173 Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 21: 26-32. PMID 10235511 DOI: 10.1097/00126334-199905010-00004 |
0.321 |
|
| 1999 |
Pelz R, Hendrix CW, Swoboda SM, Diener-West M, Merz W, Hammonds JM, Lipsett PA. A DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF PROPHYLACTIC FLUCONAZOLE TO PREVENT CANDIDA INFECTIONS IN CRITICALLY ILL SURGICAL PATIENTS Critical Care Medicine. 27: A33. DOI: 10.1097/00003246-199912001-00043 |
0.734 |
|
| 1999 |
Pelz RK, Hendrix CW, Swoboda SM, Merz WG, Lipsett PA. FLUCONAZOLE BLOOD CONCENTRATIONS AFTER ENTERAL ADMINISTRATION IN CRITICALLY-ILL SURGICAL PATIENTS EXCEED MOST CANDIDA MINIMAL INHIBITORY CONCENTRATIONS IN A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN WHICH FLUCONAZOLE PREVENTED CANDIDAL INFECTIONS Critical Care Medicine. 27: A33. DOI: 10.1097/00003246-199912001-00041 |
0.744 |
|
| 1997 |
Barditch-Crovo P, Toole J, Hendrix CW, Cundy KC, Ebeling D, Jaffe HS, Lietman PS. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)- phosphonylmethoxyethyl]adenine) in HIV-infected patients Journal of Infectious Diseases. 176: 406-413. PMID 9237705 DOI: 10.1086/514057 |
0.315 |
|
| 1994 |
Blatt SP, Dolan MJ, Hendrix CW, Melcher GP. Legionnairesș disease in human immunodeficiency virus-infected patients: eight cases and review Clinical Infectious Diseases. 18: 227-232. PMID 8161631 DOI: 10.1093/clinids/18.2.227 |
0.318 |
|
| 1994 |
Clerici M, Wynn TA, Berzofsky JA, Blatt SP, Hendrix CW, Sher A, Coffman RL, Shearer GM. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus Journal of Clinical Investigation. 93: 768-775. PMID 8113410 DOI: 10.1172/Jci117031 |
0.314 |
|
| 1994 |
Hendrix CW, Flexner C, Szebeni J, Kuwahara S, Pennypacker S, Weinstein JN, Lietman PS. Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects Antimicrobial Agents and Chemotherapy. 38: 1036-1040. PMID 8067734 DOI: 10.1128/Aac.38.5.1036 |
0.439 |
|
| 1993 |
Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, Dolan MJ, Hendrix CW, Wolf SF, Shearer GM. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro Science. 262: 1721-1724. PMID 7903123 DOI: 10.1126/Science.7903123 |
0.339 |
|
| 1992 |
Warren RQ, Anderson SA, Nkya WM, Shao JF, Hendrix CW, Melcher GP, Redfield RR, Kennedy RC. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity. Journal of Virology. 66: 5210-5. PMID 1380094 DOI: 10.1128/Jvi.66.9.5210-5215.1992 |
0.33 |
|
| 1991 |
Flexner C, Barditch-Crovo PA, Kornhauser DM, Farzadegan H, Nerhood LJ, Chaisson RE, Bell KM, Lorentsen KJ, Hendrix CW, Petty BG, Lietman PS. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection Antimicrobial Agents and Chemotherapy. 35: 2544-2550. PMID 1810188 DOI: 10.1128/Aac.35.12.2544 |
0.348 |
|
| 1991 |
Flexner C, Barditch-Crovo P, Kornhauser D, Nerhood L, Hendrix C, Lorentsen K, Farzadegan H, Petty B, Lietman P. Intravenous dextran sulfate (DS) increases circulating HIV antigen levels in patients with ARC or AIDS Antiviral Research. 15: 125. DOI: 10.1016/0166-3542(91)90240-R |
0.373 |
|
| Show low-probability matches. |